A Day in the Life of a Cell Therapy Specialist at Kite, a Gilead Company
Harnessing the Potential of Antibody Drug Conjugates in Oncology
Published on :Join us for Harnessing the Potential of Antibody Drug Conjugates (ADCs) in Oncology, on October 25 at Johnson & Johnson Innovation – JLABS @ Washington, DC. We’ll host industry thought [….]
With Pandemic in Rearview Mirror, BriaCell Charges Ahead with Cancer Immunotherapy
Published on :With Pandemic in Rearview Mirror, BriaCell Charges Ahead with Cancer Immunotherapy By Mark TerryApril 25, 2023 Many biopharma companies had to place their clinical trials on hold during the first [….]
BlueSphere Bio Aims for Next-Level Personalized Cancer Cell Therapy
Published on :Chimeric Antigen Receptor T cell (CAR-T) therapies, such as those developed by Kite Pharma, have revolutionized the approach to treating hematological cancers, but the therapies have limitations due to toxicity concerns. Pennsylvania-based BlueSphere Bio believes its approach through the use of TCR-T cell therapies will provide a more precise treatment option for patients.
Three New Members with Ties to Johns Hopkins Appointed to National Cancer Advisory Board by President Biden
Published on :WASHINGTON – Today, President Biden announced the appointment of seven distinguished clinicians and researchers to the National Cancer Advisory Board, which plays an important role in guiding the Director of the National Cancer Institute in setting the course for the national cancer research program. President Biden is committed to ending cancer as we know it – including by making sure his Administration is investing in research and development that will help advance breakthroughs to prevent, detect, and treat diseases like cancer. The National Cancer Advisory Board will compliment the Administration’s efforts to build on the spirit and learnings of the Cancer Moonshot, which President Biden led in the Obama-Biden Administration.
Ascentage Pharma and Innovent Biologics Reach Multifaceted Strategic Agreement Totaling $245M
Published on :Ascentage Pharma (6855.HK), a globally focused biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, and Innovent Biologics (1801.HK, “Innovent”), today announced a multifaceted strategic collaboration.
Gaithersburg’s Sirnaomics Secures $105 Million in Series E Financing to Fund Development of Novel RNAi Therapeutics
Published on :Proceeds to Fund Development of Novel RNAi Therapeutics for Cancers, Viral Infections, Fibrosis, and Metabolic Diseases
Gaithersburg’s miRecule Inc. closes $5.7M to Create Breakthrough RNA Therapies for Cancer and Muscular Dystrophy
Published on :miRecule, Inc. (“miRecule”), an emerging biotech company focused on the development of cutting-edge RNA therapeutics, announced today it has closed over $5.7M in seed funding. The funding round was led by Alexandria Venture Investments, along with Boutique Venture Partners, Pathway Bioventures, Alumni Ventures Group, and national angel investors, with additional funding coming from the Maryland Momentum Fund and the FSHD Society. This funding includes a non-dilutive $2M Phase II SBIR grant from the National Cancer Institute.
WindMIL Therapeutics Appoints Dr. Kimberly Noonan as Chief Science & Technology Officer
Published on :WindMIL Therapeutics, a clinical-stage company developing marrow-infiltrating lymphocytes (MILs®) for cancer immunotherapy, today announced the appointment of Co-Founder Kimberly Noonan, PhD, MPH, to Executive Vice President, Chief Science & Technology Officer. In this role, Dr. Noonan’s leadership will expand to include WindMIL’s efforts in manufacturing and manufacturing science and technology (MS&T).
Immunomic Therapeutics Announces License Agreement With Lineage Cell Therapeutics for Cancer Immunotherapy
Published on :Partnership Leverages Lineage’s Investigational VAC Allogeneic Cancer Vaccine Platform and Immunomic’s Proprietary Tumor Associated Antigen to Generate a Novel Oncology Product Candidate